Funds will support development of game-changing IUD (intrauterine device) for contraception through an IND filing in early 2025 Funds will support development of game-changing IUD (intrauterine device) for contraception through an IND filing in early 2025
The rest is here:
3Daughters Secures $4.7 Million in Oversubscribed Seed Round
DURHAM, N.C., July 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Robert “Bobby” Parks has been appointed as chief accounting officer (CAO), responsible for Fortrea’s accounting function, including financial reporting, risk, controls and compliance in accordance with applicable standards, laws and regulations.
More here:
Fortrea Appoints Robert Parks as Chief Accounting Officer
CINCINNATI, Ohio, July 11, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (“Onconetix” or the “Company”) (Nasdaq: ONCO), today announced it has entered into definitive agreements for the immediate exercise of certain existing warrants to purchase 7,458,642 shares of its common stock originally issued in August 2022 and August 2023, having exercise prices ranging from $1.09 to $2.546 per share, at a reduced exercise price of $0.15 per share. The transaction is expected to close on or about July 12, 2024, subject to satisfaction of customary closing conditions.
Visit link:
Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds
First Licensing Agreement for coactiv+™ Scalp Care Line First Licensing Agreement for coactiv+™ Scalp Care Line
Go here to see the original:
Kane Biotech Signs Worldwide License Agreement with Omni Bioceutical Innovations Inc.
NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal
Read the original here:
California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults
BOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, July 23, 2024 at 10:00 AM ET.
The rest is here:
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company’s freedom to operate in the MRD market and broadens patient access to the benefits of MRD testing.
Read the original post:
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
SALT LAKE CITY, July 11, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced plans to submit a briefing book by July 13 to the U.S. Food and Drug Administration (FDA) in advance of a granted Type C interaction. The purpose of the interaction with the FDA, to occur in the third quarter of 2024, is to receive feedback on the potential path to submission of a new drug application (NDA) for CNM-Au8® as a potential treatment for ALS via the accelerated approval pathway.
Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF)
Read more from the original source:
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment
TERMINATION OF THE LIQUIDITY CONTRACT
See the original post here:
Virbac: Termination of the liquidity contract